Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a sell rating to a hold rating in a report published on Thursday.

Several other brokerages have also weighed in on ASND. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an overweight rating in a research note on Friday, May 3rd. Cantor Fitzgerald restated an overweight rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, May 15th. Wedbush lifted their price target on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an outperform rating in a research note on Thursday, February 8th. Wells Fargo & Company lifted their price objective on Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an overweight rating in a report on Friday, May 3rd. Finally, Citigroup lifted their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $176.88.

Ascendis Pharma A/S Stock Down 1.3 %

Shares of Ascendis Pharma A/S stock opened at $129.44 on Thursday. Ascendis Pharma A/S has a twelve month low of $83.75 and a twelve month high of $161.00. The business has a 50-day moving average price of $140.60 and a 200 day moving average price of $131.36. The firm has a market cap of $7.54 billion, a PE ratio of -13.47 and a beta of 0.54.

Hedge Funds Weigh In On Ascendis Pharma A/S

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at $25,000. Private Ocean LLC purchased a new position in Ascendis Pharma A/S in the first quarter valued at $36,000. Quadrant Capital Group LLC increased its holdings in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares during the last quarter. Finally, Signaturefd LLC increased its holdings in Ascendis Pharma A/S by 31.9% in the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 193 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.